AUTHOR=Qiu Dan , Zhang Guijuan , Yan Xianxin , Xiao Xinqin , Ma Xinyi , Lin Shujun , Wu Jieyan , Li Xinyuan , Wang Wandi , Liu Junchen , Ma Yi , Ma Min TITLE=Prospects of Immunotherapy for Triple-Negative Breast Cancer JOURNAL=Frontiers in Oncology VOLUME=11 YEAR=2022 URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2021.797092 DOI=10.3389/fonc.2021.797092 ISSN=2234-943X ABSTRACT=

In the classification and typing of breast cancer, triple-negative breast cancer (TNBC) is one type of refractory breast cancer, while chemotherapy stays in the traditional treatment methods. However, the impact of chemotherapy is short-lived and may lead to recurrence due to incomplete killing of tumor cells. The occurrence, development, and relapse of breast cancer are relevant to T cell dysfunction, multiplied expression of related immune checkpoint molecules (ICIs) such as programmed death receptor 1 (PD-1), programmed cell death 1 ligand 1 (PD-L1), and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) produce immunosuppressive effect. Immunotherapy (namely, immune checkpoint inhibitors, adoptive cellular immunotherapy, CAR-T immunotherapy and some potential treatments) provides new hope in TNBC. This review focuses on the new immune strategies of TNBC patients.